"Sangamo Biosciences (SGMO) has been receiving the kind of news that biotech companies dream of, with multiple main-stream news outlets picking up the story that the company is developing what may be a 'functional cure' for AIDS," notes biotech sector specialist John McCamant.

The editor of The Medical Technology Stock Letter explains, "The treatments that SGMO is developing are exciting, and we see this stock going much higher this year and in subsequent years based on clinical progress.

Continue reading Sangamo (SGMO): An HIV Treatment Speculation

Sangamo (SGMO): An HIV Treatment Speculation originally appeared on BloggingStocks on Fri, 11 Mar 2011 10:00:00 EST. Please see our terms for use of feeds.

"As tradition holds, Celgene (CELG) gave the first presentation at the recent 29th JP Morgan Healthcare Conference, where CEO Bog Hugin focused on Celgene's ongoing plans to become a world-wide company and expansion into global markets," reports John McCamant.

The biotech specialist and editor of The Medical Technology Stock Letter explains, "They expect 2011 to be the first year where the company earns a majority of sales outside the U.S. The company is currently conducting 25 Phase III trials on its various drugs.

"Celgene also announced 4th quarter 2010 earnings last week, and revenue was down 16%, mostly based on costs incurred due to the Abraxis acquisition.

Continue reading Celgene (CELG): A Biotech Takeover Target?

Celgene (CELG): A Biotech Takeover Target? originally appeared on BloggingStocks on Tue, 15 Feb 2011 13:00:00 EST. Please see our terms for use of feeds.

"The visible growth story at Jazz Pharmaceuticals (JAZZ) is the narcolepsy treatment Xyrem, which accounts for 85% of revenues," says growth stock specialist Mike Cintolo.

The editor of Cabot Top Ten Weekly Report explains, "But Jazz has great potential to make big money with other drugs too-all of which focus on the chemistry of the brain.

"Thanks to patents, Jazz has a decade to run with Xyrem before generic competitors can enter the market. Meanwhile, its drugs have potential to treat and/or cure obsessive-compulsive disorders, anxiety disorders, fibromyalgia, epilepsy and restless leg syndrome.

Continue reading All That Jazz (JAZZ): Biotech Targets Narcolepsy, OCD and Anxiety

All That Jazz (JAZZ): Biotech Targets Narcolepsy, OCD and Anxiety originally appeared on BloggingStocks on Tue, 08 Feb 2011 11:00:00 EST. Please see our terms for use of feeds.

"Myriad Genetics (MYGN) is an innovative company that can diagnose your risk of cancer years before you have any symptoms," notes growth stock expert Lou Basenese.

The editor of White Cap Research explains, "Even better, it benefits from no competition and one of the best research and development teams around.

"Myriad Genetics' main product is called BRACAnalysis, which is a test that analyzes a woman's genetics to determine her likelihood of developing breast and ovarian cancers. Plain and simple, the test saves lives ... and money.

Continue reading Myriad Genetics (MYGN): Speculating on Cancer Diagnosis

Myriad Genetics (MYGN): Speculating on Cancer Diagnosis originally appeared on BloggingStocks on Fri, 19 Nov 2010 13:00:00 EST. Please see our terms for use of feeds.

Continue reading Amgen Posts Better-Than-Expected Q2 Earnings

Amgen Posts Better-Than-Expected Q2 Earnings originally appeared on BloggingStocks on Thu, 29 Jul 2010 17:00:00 EST. Please see our terms for use of feeds.

Continue reading Closing Bell: Decoupling of inverse dollar and stock relationship (POT, CHTT, ETFC, ATHX, V, BIIB)

Closing Bell: Decoupling of inverse dollar and stock relationship (POT, CHTT, ETFC, ATHX, V, BIIB) originally appeared on BloggingStocks on Mon, 21 Dec 2009 16:00:00 EST. Please see our terms for use of feeds.

Continue reading Biogen Idec names new chairman, announces positive drug test results

Biogen Idec names new chairman, announces positive drug test results originally appeared on BloggingStocks on Fri, 11 Dec 2009 11:40:00 EST. Please see our terms for use of feeds.

"I am recommending Celgene (NASDAQ: CELG) as part of an 'offense-defense' thesis," says Ian Wyatt. In Top Stock Insights, he reviews the leading biotechnology company.

Wyatt explains, "Celgene engages in the discovery of therapies designed to treat cancer and immune inflammatory related diseases. They have a number of products at the commercial stage including REVLIMID, THALOMID and VIDAZA.

"Celgene is also researching stem cells derived from the human placenta as well as from the umbilical cord, thus tapping into a promising new technology while avoiding the political and ethical questions dogging others involved in stem cell research.

Continue reading Celgene (CELG): Bet on biotech for 'offense and defense'

Celgene (CELG): Bet on biotech for 'offense and defense' originally appeared on BloggingStocks on Tue, 27 Oct 2009 11:20:00 EST. Please see our terms for use of feeds.

Theravance (NASDAQ: THRX) biotechnology company closed at $15.22. THRX September volatility is at 65, October is at 72, December is at 78 verses its 26-week average of 78 according to Track Data, suggesting decreasing near term price movement.

Seattle Genetics (NASDAQ: SGEN) a clinical stage biotechnology company, closed at $12.09. SGEN October and March 2010 option implied volatility of 60 is near its 26-week average according to Track Data, suggesting non-directional price movement.

Option Update is provided by Stock Specialist Paul Foster of theflyonthewall.com.

Options Update: Clinical biotechnology stocks volatility near average originally appeared on BloggingStocks on Tue, 25 Aug 2009 08:00:00 EST. Please see our terms for use of feeds.

"I'm always looking for market leadership; right now, biotechnology stocks are moving up faster than most anything else," says Ron Rowland. In Money & Markets, he eyes biotech ETFs.

"Biotechnology is a fascinating sector, one that's made (and lost) a lot of money for millions of investors in recent decades. That's why, in my opinion, you should become familiar with this industry.

"Broadly speaking, it's the application of technology to biological materials - plants, animals and people.

"Nowadays a lot of biotechnology involves manipulating genetic material: The DNA that forms the basis for life. The goal is to produce new and useful substances that make life better and, of course, turn a profit along the way.

Continue reading The best ETFs for betting on biotech

The best ETFs for betting on biotech originally appeared on BloggingStocks on Tue, 11 Aug 2009 13:50:00 EST. Please see our terms for use of feeds.

"How does one go about investing in the antibody space?" asks biotech specialist John McCamant. In The Medical Technology Stock Letter, he eyes Immunogen (NASDAQ: IMGN), and offers an in-depth report for biotech-savvy readers.

"As background, T-DM1 is a second generation Herceptin that may even exceed the original in sales because the armed antibody has been more potent to date by showing effectiveness in mBC patients who have failed either Herceptin or Tykerb.

"The company will continue to benefit from Genetech's extensive antibody experience as they continue to run all development for Immunogen's T-DM1.

Continue reading Immunogen (IMGN): Investing in antibody technology

Immunogen (IMGN): Investing in antibody technology originally appeared on BloggingStocks on Tue, 14 Jul 2009 12:00:00 EST. Please see our terms for use of feeds.

"Midyear is as good a time as any to pause and reflect," says Richard Moroney in Dow Theory Forecasts -- a newsletter with the distinction of having been published for more than 50 years.

Here, he reviews the state of the market and offers a look at trio of favorite stocks which he considers "fundamentally superior" companies: Biogen Idec (NASDAQ: BIIB), Comcast (NASDAQ: CMCSA), and Oceaneering International (NYSE: OII).

Continue reading Mid-year favorites from Dow Theory: BIIB, CMCSA, OII

Mid-year favorites from Dow Theory: BIIB, CMCSA, OII originally appeared on BloggingStocks on Fri, 26 Jun 2009 11:30:00 EST. Please see our terms for use of feeds.

"Biotech company Celgene Corp. (NASDAQ: CELG) is a prime example of a stock that plays both offense and defense," says Ian Wyatt.

In his Top Stock Insights, he explains, "The valuation is low and growth is attractive. With the pipeline of products in development, Celegene offers investors a huge upside potential."

"Celgene offers investors a steady product base, a variety of drug treatments in development and a cash pile ready to purchase existing technologies.

"Celgene engages in the discovery of therapies designed to treat cancer and immune-inflammatory related diseases. They have a number of products at the commercial stage.

Continue reading Celgene (CELG): Play offense and defense with biotech

Celgene (CELG): Play offense and defense with biotech originally appeared on BloggingStocks on Mon, 22 Jun 2009 13:40:00 EST. Please see our terms for use of feeds.

Venture capital firms Braemar Energy Ventures and Lightspeed Venture partners led the Series C round for Solazyme, Inc., putting $57 million in fresh capital into the company. This brings total outside financing to above $76 million for the algae-derived biofuels company ... and shows yet another sign of life for private investment in green technology.

Solazyme uses microalgae biotechnology for the production of clean fuels, green chemicals, edible oils, and wellness products. The company seeks to "answer the increasing global demand for clean and renewable sources of oil" through sustainable and scalable technologies. The company's renewable oil production process relies on industrial fermentation, in which the algae consume nonfood biomass and industrial byproducts, which the algae converts to oil. End products include renewable diesel, biodiesel, and jet fuel.

Continue reading VC firms look to make green on green with $57m play for Solazyme

VC firms look to make green on green with $57m play for Solazyme originally appeared on BloggingStocks on Tue, 09 Jun 2009 12:30:00 EST. Please see our terms for use of feeds.

"Genomics may be the 'next big thing' after the Internet and biotech. Finding those who can make money early onwill likely pay dividends to investors," expla]in small cap growth stock specialist Jim Oberweis, Jr.

In his The Oberweis Report, he explains the "politics" behind this bullish scenario as well as his top pick for log-term investors seeking exposure to the developing healthcare technologies if genomics and personalized medicine.

"We believe that the biotech boom was a direct consequence of rising National Health Institute (NIH) funding, cheap equity capital, and the ability to patent NIH-funded discoveries. And we see that happening again.

Continue reading Genomics: The next big thing?

Genomics: The next big thing? originally appeared on BloggingStocks on Mon, 18 May 2009 14:00:00 EST. Please see our terms for use of feeds.

Continue reading Should you invest in low priced biotech stocks like Dendreon?

Should you invest in low priced biotech stocks like Dendreon? originally appeared on BloggingStocks on Wed, 15 Apr 2009 12:45:00 EST. Please see our terms for use of feeds.

"After warning that it would only achieve the low end of its previous guidance range for 2009, Celgene (NASDAQ: CELG) sold off significantly," notes biotech expert John McCamant.

Nevertheless, in his The Medical Technology Stock Letter he sees the selloff as any opportunity, calling the company a "great growth story."

"Celgene pre-announced 1Q 09 revenues of $600 million, which was significantly below Wall Street consensus estimates of $640-$650 million.

"The earnings miss was completely unexpected, and has partially shaken the belief that the Big Bios would be able to deliver solid earnings despite the economic problems.Nevertheless, we remain positive on the CELG story.

Continue reading Celgene (CELG): Selloff creates opportunity

Celgene (CELG): Selloff creates opportunity originally appeared on BloggingStocks on Mon, 06 Apr 2009 14:30:00 EST. Please see our terms for use of feeds.

"In all the excitement over the new future for embryonic stem cell, it seems investors have forgotten about adult stem cell products," notes growth stock specialist Dave Dyer.

In his Dave Dyer's Newsletter, he explains, "In fact, there are adult stem cell products either already on the market or in late clinical trials. We view this as an excellent opportunity." Here, he looks at NuVasive (NASDAQ: NUVA).

"Stem cells can grow into any type of organ or tissue and the promise is that damaged organs may be repaired or even replaced with spare parts grown from stem cells. This amazing potential could revolutionize the life sciences.

"NuVasive is a rapidly growing company with unique technology for minimally-invasive back surgery; named Osteocel, it is a stem cell-based product used to help with bone grafts done as a part of spinal surgery.

Continue reading Nuvasive (NUVA): Growth in adult stem cells

Nuvasive (NUVA): Growth in adult stem cells originally appeared on BloggingStocks on Fri, 03 Apr 2009 14:30:00 EST. Please see our terms for use of feeds.

Despite the challenging economic environment, two leading advisors see opportunity in a biotech stock involved in developing drugs for cancer, multiple sclerosis and diabetes -- Isis Pharmaceuticals (NASDAQ: ISIS).

Here, we look at commentary from growth stock expert Toby Smith, editor of ChangeWave Investing, and biotech specialist John McCamant, editor of The Medical Technology Stock Letter.

Toby Smith explains, "For the latest quarter, revenue climbed 38% to $29.7 million. Revenue from research and development collaborations more than doubled to $29.1 million from $13 million, but licensing and royalty revenue dropped to $546,000 from $8.5 million.

Continue reading Two experts eye Isis (ISIS) as biotech bet

Two experts eye Isis (ISIS) as biotech bet originally appeared on BloggingStocks on Fri, 20 Mar 2009 13:20:00 EST. Please see our terms for use of feeds.

Just as President Obama lifted the executive order banning the use of embryonic stem cells for research, Roche and Genentech (NYSE: DNA) appear to have reached an agreement on Roche's bid to acquire the 44% of DNA that Roche does not currently own.

Shares of biotech companies engaged in stem cell protocols rallied after the Obama announcement. While most of these companies are small in size with stock prices below $2 per share, the announcement gave impetus to price increases of 17% to 100%.

Continue reading Beware biotech

Beware biotech originally appeared on BloggingStocks on Tue, 10 Mar 2009 14:40:00 EST. Please see our terms for use of feeds.